This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cyberonics Names Bruce H. KenKnight, Ph.D. Vice President, Emerging Therapies

Stocks in this article: CYBX

HOUSTON, Jan. 9, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that Bruce H. KenKnight, Ph.D., joined the company as its Vice President, Emerging Therapies, effective on January 1, 2013.  Dr. KenKnight will lead all of the company's emerging therapies programs, including the current clinical evaluation of Autonomic Regulation Therapy , an emerging therapy for treatment of chronic heart failure that incorporates Cyberonics' extensive experience delivering vagus nerve stimulation to more than 100,000 patients world-wide.

Most recently, Dr. KenKnight was President and CEO of Valtech Cardio Ltd, a privately-held company developing innovative solutions for surgical and percutaneous mitral valve repair and replacement. For the 20-year period ending in 2010, he worked at Boston Scientific Corporation (formerly Guidant Corporation), finally serving as Vice President of Research and Business Development for the Cardiac Rhythm Management Division.  Dr. KenKnight has served on the Board of Directors of seven privately-held companies and is an author of more than 150 peer-reviewed manuscripts, reviews, book chapters and conference abstracts in fields relating to cardiac electrophysiology and heart failure.  He is an editorial consultant for several cardiology journals and serves as Associate Editor for Cardiovascular Engineering and Technology.  In 2006, Dr. KenKnight received the Albert Einstein Award for Outstanding Achievement in the Life Sciences from the Global Business Leadership Council in Tel Aviv, Israel.  In 2007, he was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE).  Dr. KenKnight is also an Adjunct Professor of Biomedical Engineering at the University of Minnesota and is named as an inventor on more than 120 U.S. patents and more than 250 patents world-wide.

"Bruce has 30 years of experience developing high-value solutions to address major unmet medical needs and has consistently demonstrated the ability to drive innovative programs that lead to substantial shareholder value," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "We enthusiastically welcome Bruce to the Cyberonics team and look forward to continued progress on our emerging therapy programs, facilitating the substantial, long-term growth of the company," said Milton Morris, Ph.D., Senior Vice President, Research and Development.

Bruce received the Bachelor of Science degree in mechanical engineering, Master of Science and Ph.D. degrees in biomedical engineering from the College of Science & Technology at the University of Minnesota in Minneapolis, and has completed business management training at the Harvard School of Business, University of Chicago and the Kellogg School of Management.

About Cyberonics, Inc. and the VNS Therapy ® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs